Navigation Links
Global Standardization for Alzheimer's Biomarkers Moves a Major Step Closer to Reality

NEW YORK, Aug. 11, 2011 /PRNewswire/ -- Citeline, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials recently reviewed the findings from the 14th International Conference on Alzheimer's Disease (ICAD 2011/AAIC 2011) July 16-21, 2011, noting that while pharma continues to develop beta amyloid targeting drugs, amyloid targets are moving ahead in terms of biomarkers and early warning for risk of Alzheimer's.

According to Dr. Revati Tatake, CNS Analyst at Citeline, noteworthy among the biomarkers/genomics-focused on-going studies were multiple studies under the worldwide initiative, "Alzheimer's Disease Neuroimaging Initiative (ADNI)", spearheaded by the Alzheimer's Association in an effort to globally standardize Alzheimer's biomarkers, and the "Dominantly Inherited Alzheimer's Network (DIAN)" study.  The results from three ADNI studies from different countries suggested that a worldwide ADNI data set can be used for combined analysis of APOE-e4 on amyloid deposition, a step closer to the goal of global standardization of biomarkers. The DIAN study has a slightly different focus and indicated that abnormal levels of CSF amyloid-beta42 and tau protein, brain chemistry and imaging changes can be detected at least 10 years and up to 20 years before the expected onset of Alzheimer's in the subjects with genetic predisposition.

"The progress in Alzheimer's biomarkers/genomics field is especially significant as several clinical studies involving anti-Alzheimer's drugs are investigating CSF/plasma/brain amyloid-beta levels as one of the major efficacy biomarkers and using APOE-e4 genotype for stratifying patients for the treatment," commented Dr. Tatake.  In fact out of the 40 abstracts involving pipeline drugs presented at this meeting, 14 trials contained analysis of biomarker and/or genomic parameters.

A late breaking report concerning long-term safety results of an ongoing Phase II trial of bapineuzumab beyond 78 weeks is worth mentioning.  The long term safety data that bapineuzumab was generally well-tolerated and side-effects tended to be mild and less frequent over time are certainly encouraging, as bapineuzumab is one of the most advanced anti- beta amyloid antibodies that are in clinical development.  Bapineuzumab, jointly developed by Pfizer and J&J, is currently in several ongoing pivotal trials.

Among other approaches targeting the beta amyloid pathway, AFFiRiS/GSK presented safety data for active immunotherapy approach by AFFITOPE AD02.  Bristol-Myers Squibb and Chiesi presented safety and tolerably results of their gamma secretase inhibitors, avagacestat (BMS-708163) and CHF-5074, respectively.   The safety results of gamma secretase inhibitors are particularly important in light of termination of pivotal trials of Lilly's gamma secretase inhibitor, semagacestat, for safety reasons. "It remains to be seen if Lilly's termination of semagacestat has impacted/will impact the course for other gamma secretase inhibitors that are in clinical development," added Dr. Tatake.

About Citeline

Citeline ( provides the world's most comprehensive real-time R&D intelligence to the pharmaceutical industry, covering global clinical trial, investigator and drug intelligence. Our data is drawn from over 18,000 unique sources and analyzed by the industry's largest team – over 250 full-time expert analysts and editors.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Julie McKenna
Citeline Marketing Manager

SOURCE Citeline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017
2. Generic Drugs in Consumer Health Global Overview 2011
3. Global Health Ventures August 4th Investor Presentation Now Available for On-demand Viewing at
4. Spaulding Clinical Announces New Joint Partnership for Global Studies with Eurofins Optimed Clinical Research
5. Global GMP Guidelines Available in Online GMP Library
6. Robbins & Myers to Present at Jefferies 2011 Global Industrial Conference
7. Global Pharm Holdings Group Completes Acquisition of Pacific Asia Pharm Investment Group Co., Ltd.
8. Robertson Global Health Solutions Announces Progress Towards Commercial Venture with LifeSense
9. SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion
10. Global Health Ventures to Present Live, Online at on August 4th
11. Global Mercury Treaty May Include Ban on Mercury in Medicine
Post Your Comments:
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Un nuevo enfoque combina la inmunoterapia con la terapia ... Clinical Cancer Research . --> ...
(Date:11/26/2015)... and Markets ( ) has announced the addition of ... - Rise in Cardiac Disorders and Growing Awareness among People ... Boston scientific and others. ... others. --> The market is dominated by ... scientific and others. Asia ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
(Date:11/26/2015)... ... , ... Inevitably when people think Thanksgiving, they also think Holiday sales and ... Friday and Cyber Monday massage chair sales to receive the best pricing ... to find the best massage chair deals, they can see all of the coupons ...
Breaking Medicine News(10 mins):